List view / Grid view
27 April 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Entresto (sacubitril valsartan) for some people with heart failure.
19 April 2016 | By Victoria White, Digital Content Producer
Boehringer Ingelheim and Lilly have announced plans to conduct two trials investigating Jardiance for the treatment of people with chronic heart failure...
21 March 2016 | By Victoria White
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ heart failure drug, Entresto (sacubitrial/valsartan).
25 November 2015 | By Victoria White
The European Commission has granted marketing authorisation to Novartis’ Entresto (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).
25 September 2015 | By Victoria White
The CHMP has adopted a positive opinion for Novartis’ Entresto (sacubitril/valsartan), marking an important milestone towards the drug becoming available in the EU.
8 July 2015 | By Victoria White
The US Food and Drug Administration (FDA) has approved Novartis' Entresto (sacubitril/valsartan) tablets for the treatment of heart failure with reduced ejection fraction.
Abbott today announced CE Marking (Conformité Européenne) for the ARCHITECT Galectin-3 assay, a test to aid doctors in assessing the prognosis of patients diagnosed with chronic heart failure (HF). The test was developed in partnership with BG Medicine, Inc., (NASDAQ: BGMD) to run on Abbott’s ARCHITECT immunochemistry platform.
